Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 681

Sort by

Sort Order Select

Journal Articles

NUP98-HOXA9 -Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML

Ivan Sloma, PharmD, PhD, Philip Beer, PhD FRCPath, MRCP, Christophe Desterke, PhD, Elizabeth Bulaeva, Misha Bilenky, Michelle Moksa, Kamini Raghuram, Cedric Brimacombe, Karen Lambie, Ali G Turhan, MD PhD, Orianne Wagner-Ballon, MD PhD, Philippe Gaulard, MD PhD, R. Keith Humphries, MD PhD, Martin Hirst, PhD BS, Connie J. Eaves, PhD

Blood (2019) 134 (Supplement_1): 4139.

https://doi.org/10.1182/blood-2019-127839

Published: 2019

Journal Articles

Prognostic Effects of Pretreatment Statuses at Diagnosis in Patients with Chronic Myeloid Leukemia: Results of the New Target Observational Study 1

Takaaki ONO, MD PhD, Naoto Takahashi, MD PhD, Masahiro Kizaki, MD, Tatsuya Kawaguchi, MD, Ritsuro Suzuki, MD PhD, Kazuhito Yamamoto, Kazunori Ohnishi, MD, Tomoki Naoe, MD PhD, Itaru Matsumura, MD PhD

Blood (2019) 134 (Supplement_1): 4149.

https://doi.org/10.1182/blood-2019-122092

Published: 2019

Journal Articles

Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party

Blood (2019) 134 (Supplement_1): 2931.

https://doi.org/10.1182/blood-2019-125052

Published: 2019

Journal Articles

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Blood (2019) 134 (Supplement_1): 2935.

https://doi.org/10.1182/blood-2019-129825

Published: 2019

Journal Articles

Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Fernanda F Engelbrecht, Eliana C Miranda, PhD, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD

Blood (2019) 134 (Supplement_1): 2938.

https://doi.org/10.1182/blood-2019-129388

Published: 2019

Journal Articles

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

Aishwarya Krishnan, Maria Pagane, Mikhail Roshal, MD PhD, Erin McGovern, BA, Zoe Stone-Molloy, Janice Chen, PhD, Christopher Brooks, PhD, Ross L. Levine, MD, Raajit K. Rampal, MD PhD

Blood (2019) 134 (Supplement_1): 2967.

https://doi.org/10.1182/blood-2019-129397

Published: 2019

Journal Articles

Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)

Jorge Cortes, MD, Hagop M. Kantarjian, MD, Guillaume Richard-Carpentier, MD, Gautam M. Borthakur, MD, Farhad Ravandi, MD, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Tapan M. Kadia, MD, Srdan Verstovsek, MD PhD, Guillermo Garcia-Manero, MD, Courtney D. DiNardo, MDMSc, Naveen Pemmaraju, MD, Naval G. Daver, MD, Prithviraj Bose, MD, Sherry A. Pierce, BSN, BA, Samuel Dara, MBBS, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2941.

https://doi.org/10.1182/blood-2019-121784

Published: 2019

Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Blood (2019) 134 (Supplement_1): 2924.

https://doi.org/10.1182/blood-2019-128761

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Blood (2019) 134 (Supplement_1): 495.

https://doi.org/10.1182/blood-2019-130043

Published: 2019

Journal Articles

An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3 rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia

Qian Jiang, MD, Xiaojun Huang, MD, Zi Chen, MD, Qian Niu, Lichuang Men, Hengbang Wang, PhD, Jiao JI, PhD MD, Bo Huang, Dayu Shi, Ting Zhao, Yue Hou, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2019) 134 (Supplement_1): 493.

https://doi.org/10.1182/blood-2019-124295

Published: 2019

Journal Articles

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Ekin Kircali, Guldane Cengiz Seval, Sinem Civriz Bozdag, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Gunhan Gurman, MD, Osman Ilhan, Hamdi Akan, MD, Meral Beksac, MD, Pervin Topcuoglu, MD

Blood (2019) 134 (Supplement_1): 4156.

https://doi.org/10.1182/blood-2019-127622

Published: 2019

Journal Articles

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Blood (2019) 134 (Supplement_1): 4158.

https://doi.org/10.1182/blood-2019-129751

Published: 2019

Journal Articles

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Naoto Takahashi, MD PhD, Itaru Matsumura, MD PhD, Shin Fujisawa, MD, Kenichi Ishizawa, MD PhD, Takaaki ONO, MD PhD, Emiko Sakaida, MD PhD, Naohiro Sekiguchi, MD PhD, Yusuke Tanetsugu, Kei Fukuhara, Masayuki Ohkura, Yuichiro Koide, Masayuki Hino, MD PhD

Blood (2019) 134 (Supplement_1): 4159.

https://doi.org/10.1182/blood-2019-121809

Published: 2019

Journal Articles

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Kirk Cahill, MD, Anand Ashwin Patel, MD, Hongtao Liu, MD PhD, Sandeep Gurbuxani, MBBS, PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Wendy Stock, MD, Jeremy Segal, MD PhD, Olatoyosi Odenike, MD

Blood (2019) 134 (Supplement_1): 4176.

https://doi.org/10.1182/blood-2019-122380

Published: 2019

Journal Articles

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

Raajit K. Rampal, MD PhD, Srdan Verstovsek, MD PhD, Sean M. Devlin, PhD, Amber C. King, PharmD, BCOP, Eytan M. Stein, MD, Naveen Pemmaraju, MD, Michael J. Mauro, MD, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Kelsey Alvarez, RN, Nicole Ard, Tawni Goodman, Bria Taylor, Prithviraj Bose, MD

Blood (2019) 134 (Supplement_1): 4163.

https://doi.org/10.1182/blood-2019-127661

Published: 2019

Journal Articles

Landscape of TP53 Mutations in MPN

Noushin Farnoud, PhD, Christopher Famulare, MS, Elli Papaemmanuil, PhD, Erin McGovern, BA, Juan Medina, MS, Juan E. Arango Ossa, BS, Raajit K. Rampal, MD PhD, Bing Li, MD, Ross L. Levine, MD, John Mascarenhas, MD, Rona Singer Weinberg, PhD, Minal A Patel, MPH, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 1681.

https://doi.org/10.1182/blood-2019-132014

Published: 2019

Journal Articles

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

Alessandra Iurlo, MD PhD, Mario Annunziata, MD, Francesco Albano, MD, Luigia Luciano, MD, Raffaele Spadano, MD, Anna Rita Scortechini, MD, Massimiliano Bonifacio, MD, Elisabetta Abruzzese, MD, Monia Lunghi, MD PhD, Alessandra Malato, MD PhD, Nicola Di Renzo, MD, Alfonso Piciocchi, Angela Pellegrino, MSc, Claudia Galimberti, Robin Foà, MD, Massimo Breccia, MD

Blood (2019) 134 (Supplement_1): 1652.

https://doi.org/10.1182/blood-2019-126098

Published: 2019

Journal Articles

ABL Kinase Domain Mutation in Chronic Myeloid Leukemia - Compliance to Imatinib Matters

Jayachandran PK, MD MRCP, DM, Trivadi S Ganesan, MD FRCP, PhD, Nikita Mehra, MD DM, Krishnarathinam Kannan, MD DM, Manikandan Dhanushkodi, MD DM, Venkatraman Radhakrishnan, MD DM, Arun Kumar Rajan, MD DM, Joshi Archit Girishchandra, MD DM, Gangothri Selvarajan, MD DM, Parathan Karunakaran, MD DM, Tenali Gnana Sagar, MD DM

Blood (2019) 134 (Supplement_1): 1654.

https://doi.org/10.1182/blood-2019-125998

Published: 2019

Journal Articles

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Pinkal Desai, MDMPH, Niamh Savage, BA, Spencer Krichevsky, BS, Tania Curcio, Sangmin Lee, MD, Michael B. Samuel, MD, Ellen K. Ritchie, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1666.

https://doi.org/10.1182/blood-2019-127663

Published: 2019

Journal Articles

Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study)

Haruko Shima, MD PhD, Akiko Kada, MPH, Akihiko Tanizawa, MD PhD, Yuki Yuza, MD PhD, Akihiro Watanabe, Masaki Ito, MD, Hideko Uryu, Katsuyoshi Koh, MD, Chihaya Imai, MD PhD, Nao Yoshida, MD PhD, Yuhki Koga, MD, Naoto Fujita, MD PhD, Akiko M Saito, MD PhD, Souichi Adachi, MD PhD, Eiichi Ishii, MD PhD, Hiroyuki Shimada, MD PhD

Blood (2019) 134 (Supplement_1): 25.

https://doi.org/10.1182/blood-2019-122623

Published: 2019

NARROW

NUP98-HOXA9 -Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML

Prognostic Effects of Pretreatment Statuses at Diagnosis in Patients with Chronic Myeloid Leukemia: Results of the New Target Observational Study 1

Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3 rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

Landscape of TP53 Mutations in MPN

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

ABL Kinase Domain Mutation in Chronic Myeloid Leukemia - Compliance to Imatinib Matters

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only